Helmuth van Es
Advisor, Strategic Corporate Development
Helmuth started his biotech career as a senior scientist at Crucell formerly IntroGene in Leiden, The Netherlands in 1994 and is a co-founder of Galapagos. At Galapagos he was Head of Science of the Leiden site of Galapagos until 2006. He co-developed the strategy of the company that moved from a functional genomics adenoviral RNAi technology platform to a biology driven, drug discovery and development company. In 2005 he founded BioConsilium which offers strategic, scientific and corporate expertise, a no-nonsense approach his network to companies, investors and academic research groups. From 2006 onwards he was CSO of Stem Cell Innovations Leiden until 2008. He is co-founder and director R & D of Audion Therapeutics a regenerative medicine, small molecule based company focusing on hearing loss based on intellectual property from the MEEI in Boston a Harvard Medical School affiliate. He is shareholder and non-executive board member of Antabio in Toulouse, a startup focussing on a new generation of antibacterials and serves on the board of Spinnovation Analytical. At ModiQuest he focusses on taking the organisation to the next level, by developing a strategy for its internal programs, optimising the organisation and attracting new partners and investors.
Advisor, Business and Corporate Development
Laurens is a biotech and pharma start-up and business development professional. He is the co-founder and CEO of Chamaeleo Pharma NV (a cancer drug development company), and the co-founder of Tillia Pharma Co. Ltd. (a Hong Kong-based pharmaceutical services business) and FORMAC Pharmaceuticals NV (a drug delivery and development company). Previously, he was also involved in the creation of PharmAbs (the KU Leuven Antibody Centre) and Cell Vir Pharmaceuticals NV (an anti-HIV drug discovery firm). Laurens started his career at Galapagos NV (drug development) as a Manager of Business Development. Besides his start-up and business development activities, Laurens has also been an active member of EuropaBio (the European Association for Bio-industries) lobbying the European Commission and the European Investment Fund where he was the key driver for the successful implementation of the Young Innovative Entreprise (YIE) status providing additional funding aids to high-growth potential companies. Laurens holds a Masters of Science Degree in Bio-engineering from the University of Ghent and a Master Degree in Finance from the Solvay Business School. At ModiQuest, Laurens is involved in supporting the development ofthe business and corporate development strategy, as well as the implementation thereof.